



## **ZSTK474**

Catalog No: tcsc0083

Available Sizes
Size: 10mg
Size: 50mg
Size: 100mg
Size: 200mg
Size: 500mg
Size: 1g
Size: 2g
Specifications
CAS No: 475110-96-4
Formula: C <sub>19</sub> H <sub>21</sub> F <sub>2</sub> N <sub>7</sub> O <sub>2</sub>
Pathway: PI3K/Akt/mTOR;Autophagy
Target: PI3K;Autophagy
Purity / Grade: >98%
Solubility: 10 mM in DMSO





## **Observed Molecular Weight:**

417.41

## **Product Description**

ZSTK474 is an ATP-competitive pan-class I **PI3K** inhibitor with **IC**<sub>50</sub>s of 16 nM, 44 nM, 4.6 nM and 49 nM for PI3K $\alpha$ , PI3K $\beta$ , PI3K $\delta$  and PI3K $\gamma$ , respectively.

IC50 & Target: IC50: 16 nM (PI3Kα), 44 nM (PI3Kβ), 4.6 nM (PI3Kδ), 49 nM (PI3Kγ) $^{[1]}$ 

In Vitro: Lineweaver-Burk plot analysis revealed that ZSTK474 inhibits all four PI3K isoforms in an ATP-competitive manner. The  $K_i$  values determined for the four PI3K isoforms showed that ZSTK474 inhibited the PI3Kδ isoform most effectively with a  $K_i$  of 1.8 nM, whereas the other isoforms are inhibited with 4-10-fold higher  $K_i$  values. Therefore, ZSTK474 should be regarded as a pan-PI3K inhibitor. We also determined the IC $_{50}$  values for inhibiting the four PI3K isoforms with ZSTK474 and LY294002. The IC $_{50}$  values of ZSTK474 (16, 44, 4.6 and 49 nM for PI3Kα, PI3Kδ and PI3Kγ, respectively) are shown to be consistent with the  $K_i$  values (6.7, 10.4, 1.8 and 11.7 nM for PI3Kα, PI3Kδ and PI3Kγ, respectively), which further supported the idea that ZSTK474 inhibits PI3Kδ most potently. Even at a concentration of 100 μM, ZSTK474 inhibits mTOR activity rather weakly<sup>[1]</sup>.

*In Vivo:* In mice subjected to MCAO, treatment with ZSTK474 is tested at dosages of 50, 100, 200, and 300 mg/kg. Since the 200 mg/kg dose produces significant improvement and no obvious toxic effects (P[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!